Neurocrine Biosciences (NBIX) announced the launch of a new sprinkle formulation of INGREZZA capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA SPRINKLE capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA. The company received FDA approval of INGREZZA SPRINKLE on April 30.
Eiry Roberts, Chief Medical Officer, Neurocrine Biosciences, said: "We wanted to provide this new option to patients and their caregivers who want the benefit of treatment with INGREZZA without the challenge of swallowing a capsule."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.